Prostate cancer impacts millions of men worldwide and causes significant disease burden. Glycosylation is the post-translational modification offering novel therapeutics for prostate cancer. The scRNA-seq data is combined with bulk RNA-seq data of prostate cancer to understand the glycosylation role and identify the therapeutic targets. This study aims to investigate the differences within tumor and the role of glycosylation. The findings confirm that glycosylation can establish multiple cell biomarkers and divide the cell subtypes of prostate cancer. The specific cell subtypes have diverse functions in cell interactions, transcript activity, prognosis and immunotherapy response, such as UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7+ (GALNT7+) epithelial cells and UDP Glucose Ceramide Glucosyltransferase+ (UGCG+) cancer associated macrophages. These outcomes assist in the better understanding of prostate cancer and provide new approach of the targeted therapy.